The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma

Neoplasia (United States)

Volumn 14, Issue 11, 2012, Pages 1075-1086

  Stead, Lucy F ^a   Berri, Stefano ^a   Wood, Henry M ^a   Egan, Philip ^a   Conway, Caroline ^a   Daly, Catherine ^a   Papagiannopoulos, Kostas ^b   Rabbitts, Pamela ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; MICRORNA; SMALL NUCLEAR RNA; SMALL NUCLEOLAR RNA; TRANSCRIPTOME; UNTRANSLATED RNA;

ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE LOSS; GENE MAPPING; GENE MUTATION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; LUNG SQUAMOUS CELL CARCINOMA; PLOIDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOGENE; SEQUENCE ALIGNMENT; TRANSCRIPTION REGULATION;

EID: 84869186340     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121380     Document Type: Article

References (91)

1. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958-967.
2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S-I, Watanabe H, Kurashina K, Hatanaka H, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139.
4. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl JMed 361, 947-957.
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11, 121-128.
6. Janssen-Heijnen MLG and Coebergh J-WW (2001). Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 31, 123-137.
7. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
8. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin M-L, Beare D, Lau KW, Greenman C, et al. (2010). A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190.
9. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, et al. (2010). The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465, 473-477.
10. Rabbitts P, Douglas J, Daly M, Sundaresan V, Fox B, Haselton P, Wells F, Albertson D, Waters J, and Bergh J (1989). Frequency and extent of allelic loss in the short armof chromosome 3 in nonsmall-cell lung cancer. Genes Chromosomes Cancer 1, 10.
11. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, Carnevali P, Nazarenko I, Nilsen GB, Yeung G, et al. (2010). Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81.
12. Wood HM, Belvedere O, Conway C, Daly C, Chalkley R, Bickerdike M, McKinley C, Egan P, Ross L, Hayward B, et al. (2010). Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed parafin-embedded specimens. Nucleic Acids Res 38, e151.
13. Hackenberg M, Sturm M, Langenberger D, Falcón-Pérez J, and Aransay A (2009). Ranalyzer: a micro RNA detection and analysis tool for next-generation sequencing experiments. Nucleic Acids Res 37, W68-W76.
14. Langmead B, Trapnell C, Pop M, and Salzberg S (2009). Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol 10, R25.
15. Complete Genomics Incorporated (2012). Available at: http://cgatools.sourceforge.net/docs/1.3.0/cgatools-methods.pdf. Accessed April 8, 2012.
16. Gusnanto A, Wood HM, Pawitan Y, Rabbitts P, and Berri S (2012). Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data. Bioinformatics 28, 40-47.
17. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Chen Y, Clapham P, Coates G, Fairley S, Fitzgerald S, et al. (2011). Ensembl 2011. Nucleic Acids Res 39, D800-D806.
18. Paşaniuc B, Zaitlen N, and Halperin E (2011). Accurate estimation of expression levels of homologous genes in RNA-seq experiments. J Comput Biol 18, 459-468.
19. Huang DW, Sherman BT, and Lempicki RA (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1-13.
20. Lu M, Shi B, Wang J, Cao Q, and Cui Q (2010). TAM: a method for enrichment and depletion analysis of a microRNA category in a list of microRNAs. BMC Bioinformatics 11, 419.
21. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, DiMaio JM, et al. (2004). Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64, 9027-9034.
22. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A, et al. (2002). Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 62, 6240-6245.
23. Järvinen A-K, Autio R, Kilpinen S, Saarela M, Leivo I, Grénman R, Mäkitie AA, and Monni O (2008). High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. Genes Chromosomes Cancer 47, 500-509.
24. Myllykangas S, Junnila S, Kokkola A, Autio R, Scheinin I, Kiviluoto T, Karjalainen-Lindsberg M-L, Hollmén J, Knuutila S, Puolakkainen P, et al. (2008). Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer 123, 817-825.
25. Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E, and Testa JR (1997). Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res 57, 2116-2120.
26. Danner BC, Hellms T, Jung K, Gunawan B, Didilis V, Füzesi L, and Schöndube FA (2011). Prognostic value of chromosomal imbalances in squamous cell carcinoma and adenocarcinoma of the lung. Ann Thorac Surg 92, 1038-1043.
27. Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W, Postma DS, Groen HJM, and van den Berg A (2009). Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer 66, 372-378.
28. Belvedere O, Berri S, Chalkley R, Conway C, Barbone F, Pisa F, Maclennan K, Daly C, Alsop M, Morgan J, et al. (2011). A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma. Genomics 99, 18-24.
29. Kim T-M, Yim S-H, Lee J-S, Kwon M-S, Ryu J-W, Kang H-M, Fiegler H, Carter NP, and Chung Y-J (2005). Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 11, 8235-8242.
30. Yan W, Song L, Liang Q, and Fang Y (2005). Progression analysis of lung squamous cell carcinomas by comparative genomic hybridization. Tumor Biol 26, 158-164.
31. McCaughan F, Pole JCM, Bankier AT, Konfortov BA, Carroll B, Falzon M, Rabbitts TH, George PJ, Dear PH, and Rabbitts PH (2010). Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med 182, 83-91.
32. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et al. (2009). SOX2 is an amplified lineagesurvival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41, 1238-1242.
33. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembel D, Martinet N, Thibault C, Huelsken J, Brambilla E, et al. (2010). SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5, e8960.
34. Meehan M, Parthasarathi L, Moran N, Jefferies C, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AWM, et al. (2012). Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene. Mol Cancer 11, 6.
35. Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M, Szaumkessel M, Pelinska K, Kiwerska K, Tönnies H, Grenman R, et al. (2011). High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. Genes Chromosomes Cancer 50, 154-166.
36. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez- Cespedes M, Minna JD, and Yokota J (2010). A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 49, 342-352.
37. Sclafani R and Schauer I (1996). Cell cycle control and cancer: lessons from lung cancer. J Investig Dermatol Symp Proc 1, 5.
38. Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K, Drabkin H, Gemmill R, Ahrent S, Sidransky D, et al. (1997). Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res 57, 1-6.
39. Panani AD, Maliaga K, Babanaraki A, and Bellenis ION (2009). Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res 29, 4483-4487.
40. Kraunz KS, Nelson HH, Lemos M, Godleski JJ, Wiencke JK, and Kelsey KT (2006). Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. Int J Cancer 118, 1364-1369.
41. Elkiran E, Mar N, Aygen B, Gursu F, Karaoglu A, and Koca S (2007). Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 7, 48.
42. Tymms MJ, Ng AY, Thomas RS, Schutte BC, Zhou J, Eyre HJ, Sutherland GR, Seth A, Rosenberg M, Papas T, et al. (1997). A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene 15, 2449-2462.
43. Oliver JR, Kushwah R, Wu J, Pan J, Cutz E, Yeger H, Waddell TK, and Hu J (2011). Elf3 plays a role in regulating bronchiolar epithelial repair kinetics following Clara cell-specific injury. Lab Invest 91, 1514-1529.
44. Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, and Kobayashi H (2011). Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J TranslMed 9, 191.
45. Watanabe T, Miura T, Degawa Y, Fujita Y, Inoue M, Kawaguchi M, and Furihata C (2010). Comparison of lung cancer cell lines representing four histopathological subtypes with gene expression profiling using quantitative real-time PCR. Cancer Cell Int 10, 2.
46. Bauer M, Aust G, and Schumacher U (2004). Different transcriptional expression of KIAA1324 and its splicing variants in human carcinoma cell lines with different metastatic capacity. Oncology Rep 11, 3.
47. Deng L, Feng J, and Broaddus RR (2010). The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis 1, e32.
48. Dompe N, Rivers CS, Li L, Cordes S, Schwickart M, Punnoose EA, Amler L, Seshagiri S, Tang J, Modrusan Z, et al. (2011). A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proc Natl Acad Sci USA 108, E943-E951.
49. Subramani D and Alahari S (2010). Integrin-mediated function of Rab GTPasesin cancer progression. Mol Cancer 9, 312.
50. Dranoff G (2004). Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4, 11-22.
51. Fukuyama T, Ichiki Y, Yamada S, Shigematsu Y, Baba T, Nagata Y, Mizukami M, Sugaya M, Takenoyama M, Hanagiri T, et al. (2007). Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/ immunological responses both in vivo and in vitro. Cancer Sci 98, 1048-1054.
52. Qi C, Zhu YT, Hu L, and Zhu Y-J (2009). Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer 124, 793-798.
53. Chen S, Lin C, Chen Y, Fang H, Cheng C, Chang C, Chen R, Tai H, Lee C, Chou M, et al. (2006). Aberrant promoter methylation of EDNRB in lung cancer in Taiwan. Oncology Rep 15, 5.
54. Ladanyi M and Pao W (2008). Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21, S16-S22.
55. Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM, Nunez MI, Behrens C, Yee J, et al. (2012). Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One 7, e37775.
56. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
57. Costa FF (2005). Non-coding RNAs: new players in eukaryotic biology. Gene 357, 83-94.
58. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C, Hung T, Argani P, Rinn JL, et al. (2010). Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076.
59. Marshall L and White RJ (2008). Non-coding RNA production by RNA polymerase III is implicated in cancer. Nat Rev Cancer 8, 911-914.
60. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, et al. (2008). MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26, 462-469.
61. Mattick J (2007). A new paradigm for developmental biology. J Exp Biol 210, 1526-1547.
62. Guttman M, Amit I, Garber M, French C, Lin M, Feldser D, Huarte M, Zuk O, Carey B, and Cassady J (2009). Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223-227.
63. Liao J, Yu L, Mei Y, Guarnera M, Shen J, Li R, Liu Z, and Jiang F (2010). Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer 9, 198.
64. Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T, and Sharp PA (2012). Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell 21, 848-855.
65. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, and Jacks T (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105, 3903-3908.
66. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64, 3753-3756.
67. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, et al. (2010). Micro RNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16, 430-441.
68. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, and Westra WH (2010). Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16, 610-619.
69. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, et al. (2012). KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18, 375-377.
70. Yin D-T, Wang L, Sun J, Yin F, Yan Q, Shen R-L, Gao J-X, and He G (2010). Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma. Ann Clin Lab Sci 40, 267-272.
71. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al. (1996). The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84, 587-597.
72. Mandai M, Konishi I, Kuroda H, Nanbu K, Matsushita K, Yura Y, Hamid AA, and Mori T (1998). Expression of abnormal transcripts of the FHIT (Fragile Histidine Triad) gene in ovarian carcinoma. Eur J Cancer 34, 745-749.
73. Prakash T, Sharma VK, Adati N, Ozawa R, Kumar N, Nishida Y, Fujikake T, Takeda T, and Taylor TD (2010). Expression of conjoined genes: another mechanism for gene regulation in eukaryotes. PLoS One 5, e13284.
74. Kim R, Kim A, Choi S-H, Kim D-S, Nam S-H, Kim D-W, Kim D-W, Kang A, Kim M-Y, Park K-H, et al. (2012). Novel mechanism of conjoined gene formation in the human genome. Funct Integr Genomics 12, 45-61.
75. Rackham O, Davies SMK, Shearwood A-MJ, Hamilton KL, Whelan J, and Filipovska A (2009). Pentatricopeptide repeat domain protein 1 lowers the levels of mitochondrial leucine tRNAs in cells. Nucleic Acids Res 37, 5859-5867.
76. Lemarie A and Grimm S (2011). Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer? Oncogene 30, 3985-4003.
77. Faghihi MA and Wahlestedt C (2009). Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol 10, 637-643.
78. Hu Q, Lu J-F, Luo R, Sen S, and Maity SN (2006). Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res 34, 6272-6285.
79. Imbriano C, Gnesutta N, and Mantovani R (2012). The NF-Y/p53 liaison: well beyond repression. Biochim Biophys Acta 1825, 131-139.
80. Sasajima Y, Tanaka H, Miyake S, and Yuasa Y (2005). A novel EID family member, EID-3, inhibits differentiation and forms a homodimer or heterodimer with EID-2. Biochem Biophys Res Commun 333, 969-975.
81. Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H, Liu S-C, Low PS, Rouleau GA, Mohandas N, et al. (1998). The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 23, 281-282.
82. Haitina T, Lindblom J, Renström T, and Fredriksson R (2006). Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics 88, 779-790.
83. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, and Lam WL (2006). High resolution analysis of nonsmall cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118, 1556-1564.
84. Qian J and Massion P (2008). Role of chromosome 3q amplification in lung cancer. J Thorac Oncol 3, 4.
85. Zabarovsky ER, Lerman MI, and Minna JD (2002). Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21, 21.
86. Kang J, Lee SY, Lee SY, Kim YJ, Park JY, Kwon SJ, Na MJ, Lee EJ, Jeon HS, and Son JW (2012). MicroRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exp Ther Med 3, 149-153.
87. Visone R and Croce CM (2009). MiRNAs and cancer. Am J Pathol 174, 1131-1138.
88. Keller A, Backes C, Leidinger P, Kefer N, Boisguerin V, Barbacioru C, Vogel B, Matzas M, Huwer H, Katus HA, et al. (2011). Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol BioSyst 7, 3187-3199.
89. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103, 2257-2261.
90. The Cancer Genome Atlas Network (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525.
91. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al. (2012). Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120.